Subchronical treatment with Fluoxetine modifies the activity of the MCHergic and hypocretinergic systems. Evidences from peptide CSF concentration and gene expression

Bruno F. Calegare, Alicia Costa, Leandro Fernandes, Ana L. Dias, Pablo Torterolo, Vânia D’Almeida

Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil
Department of Physiology, School of Medicine, Universidad de la República, Montevideo, Uruguay

1. Introduction

Major depressive disorder (MD) is a serious, recurrent, heterogeneous, and disabling psychiatric illness, that will affect one out of five people in their lifetime and is the leading cause of disability worldwide; however, the current knowledge about the mechanisms associated with the pathogenesis of this disease is still limited, and current treatments remain ineffective in a large subset of patients [2,15,22].

In accordance with the monoamine theory of MD, the main classes of antidepressants are directed to elevate the synaptic levels of monoamines in the brain. However, these drugs are associated with several limitations, which include limited clinical efficacy, therapeutic lag with high risk of suicide and morbidity during latent period and treatment resistant cases [32,36]. Therefore, in order to improve the understanding of MD and its treatment, the study of the contribution of other neuromodulatory systems in this pathology is warranted.

The hypothalamus is considered the highest hierarchical structure in the control of homeostasis, and the postero-lateral region has been considered an integrative area involved in mediating different behaviors and processes that are critical to this function. Within this and adjacent regions of the hypothalamus, there are neurons that utilize the neuropeptides melanin-concentrating hormone (MCH) or hypocretin-1 and 2 (also called orexin A and B, respectively) as neuromodulators [4,27]. Both groups of neurons project throughout the central nervous system [4,27].
Interestingly, while hypocretins have mainly an excitatory synaptic action, MCH has the opposite effect, and whereas the MCHergic system tends to conserve energy, the hypocretinergic system is considered to have catabolic survival functions [7,28]. Moreover, whereas the hypocretinergic neurons are involved in the generation and maintenance of wakefulness and degeneration of these neurons produces narcolepsy, a sleep pathology, the MCHergic system promotes sleep, mainly rapid eyes movement (REM) sleep [33,34].

The hypocretinergic system has been involved in mood regulation and reward; however, the precise role of hypocretins in behavioral and neurophysiological impairments observed in depression is still unclear. The fact that both hypactivity and hyperactivity of the hypocretinergic system have been found to be associated with depression (see [24] for a comprehensive review), may reflect the heterogeneous nature of MD.

Borowsky et al. [5] have demonstrated in rats that the MCH-R1 antagonist SNAP-7941 has an antidepressant-like profile in the forced-swim test (FST, a widely used experimental paradigm for screening antidepressant activity), suggesting that MCH is a pro-depressant neuromodulator. This finding was confirmed by preclinical studies [6,8,11,12,19,35,38], but the mechanism by which the MCHergic system participates in mood regulation is still unknown. However, recent studies showed that MCH suppresses the activity of presumed serotoninergic neurons of the dorsal raphe nucleus (DRN) [9], and decreases the release of serotonin within this nucleus [37]; by this means, MCH might promote a depressive mood [19].

Recently, Schmidt et al. [30] showed that MCH serum level decreases in patients with MD during antidepressant treatment. In the present study, with the hypothesis that antidepressant pharmacological treatment decreases MCHergic activity, we analyzed the MCH concentration in the cerebro-spinal fluid (CSF) as well as the hypothalamic expression of the preproMCH (Pmch) gene in rats, following subchronical treatment with Fluoxetine (FLX), an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) group [40]. In order to know if FLX also modulates the hypocretinergic system, hypocretin-1 levels in the CSF and preprohypocretin (Hcrt) gene expression were also analyzed.

2. Methods

Twenty Wistar adult male rats (280–300 g) were used in this study. The animals were maintained with food and water ad libitum, and kept under controlled conditions (temperature 22 ± 2 °C; 12:12-h light-dark cycle). All of the experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (8th edition, National Academy Press, Washington DC, 2010) and approved by the Institutional Animal Care Commission. Adequate measures were taken to minimize pain, discomfort and stress of the animals. All efforts were made in order to use the minimal number of animals necessary to produce reliable scientific data.

2.1. Experimental procedure

Fluoxetine hydrochloride was kindly donated by Gador Laboratories (Montevideo-Uruguay) in powder form. Animals (n = 10) were treated with three doses of FLX (each of 20 mg/kg, i. p.) 23 h, 5 h and 1 h before CSF extraction and euthanasia. This treatment was chosen because it reversed the pro-depressive effect of MCH [19]. Control group (n = 10) received vehicle (saline) injections under the same schedule.

As in a previous study, CSF taps from the cisterna magna were performed under ketamine (90 mg/kg) and xylazine (5 mg/kg) anesthesia using a 1-ml syringe connected to a 27.5-G needle [10]. The taps were carried out during the light phase (8 h after the light was on). CSF limpid aliquots (100–150 μL) were frozen immediately over dry ice and stored at −80 °C until used. Thereafter, euthanasia was performed by decapitation. CSF samples with blood were discarded.

2.2. CSF analysis

CSF levels of MCH and hypocretin-1 were measured by means of fluorescent immunoassay kits (Phoenix Pharmaceuticals, CA, USA) [10]. These fluorescence immunoassay kits were designed to detect very specifically MCH or hypocretin-1 in a range of 0–10,000 pg/ml based on the principle of “competitive” enzyme immunoassay. The concentrations of the samples were within the linear range of the standard curve provided by each kit; the results we obtained displayed high accuracy and reproducibility.

Both hypocretin-1 and MCH were quantified in the same CSF sample. In order to determine the concentration of one of these neuropeptides, 50 μL of CSF were assayed in duplicates; the mean of both measures was considered the concentration of the peptide for the corresponding animal. The samples were incubated in an immunoplate with 25 μL of rabbit anti-MCH or anti-hypocretin-1 antibodies at 4 °C for 20 h. Next, 25 μL of the corresponding biotinilated peptide was introduced and the samples were incubated at room temperature for 1.5 h. The immunoplates were washed four times with 200 μL of assay buffer. Subsequently, 100 μL of streptavidin-horseradish peroxidase was applied, and the samples were incubated at room temperature for 1 h. After incubation, the immunoplates were washed four times with 200 μL of assay buffer. Next, 100 μL of substrate solution was applied and the samples were incubated at room temperature for 20 min. The reaction was terminated by adding 100 μL of stop solution. The fluorescence product was detected (excitation 325 nm; emission 420 nm) using a SpectraMax M2 fluorometer (Molecular Devices, Sunnyvale, CA, USA). The fluorescence readings were corrected using blanks, and the results were compared to their respective standard curves.

2.3. Gene expression analyses

Gene expression was analyzed as in a previous study of our group [10]. After euthanasia, the brains were immediately removed and the hypothalami were harvested, frozen immediately over dry ice, and stored in microtubes at −80 °C until used. RNA was extracted using Brazol reagent (LGC Biotecnologia). The quantity and quality of the RNA extracted was measured using the Nanodrop 8000 spectrophotometer (Thermo Scientific). Total RNA (1 μg) was used to synthesize the complementary DNA (cDNA) using ImProm-II Reverse Transcriptase (Promega).

Diluted cDNA sample was used as template for real-time PCR amplification using 2X Maxima SYBR GREEN/ROX qPCR Master Mix (Thermo Scientific) and the respective primers for Pmch (NCBI Gen Bank accession number: Pmch mRNA, NM_012625.1) and Hcrt (NCBI Gen Bank accession number: Hcrt mRNA, NM_013179.2). Amplification and detection were performed using an Applied Biosystems 7500 Real-Time PCR system. A two-step cycling protocol was used.

Target mRNA levels were normalized for each well to endogenous control; beta actin (NCBI Gen Bank accession number: beta actin mRNA, NM_031144) and alpha tubulin 1a (NCBI Gen Bank accession number: Tuba1a mRNA, NM_022298.1) were used to confirm the results. PCR products were subjected to a heat dissociation protocol (gradual increase of temperature from 60 to 95 °C) for melting curve analyses.

The relative gene expression was calculated using the comparative Ct (2−deltadelta Ct) method [20].
2.4. Statistics

The data are reported as the means ± S.D. All the parameters were tested concerning normality (Kolmogorov-Smirnov’s test) and homogeneity (Levene’s Test). While CSF data showed a parametric distribution, gene expression data were non-parametric; so, these data were normalized using the Z-score to allow the utilization of parametric tests. The significance of the mean between the peptides concentrations, the MCH/hypocretin-1 CSF ratio (that was calculated for each CSF sample) or mRNA levels following vehicle and FLX treatments, was analyzed by the two-tailed unpaired Student t test. The level of significance was set at p < 0.05.

3. Results

In control condition (vehicle treatment) the concentration of MCH in the CSF was 146.6 ± 60.5 pg/ml, while the concentration of hypocretin-1 was 218.5 ± 53.8 pg/ml. As it is shown in Fig. 1(A), FLX treatment decreased the CSF level of MCH (69.8 ± 31.4 pg/ml, 47.6% of the control, p = 0.004, t = 3.34). FLX did not modify the hypocretin-1 concentration (206.5 ± 51.7 pg/ml, p = 0.63, t = 0.48) (Fig. 1B). We also analyzed for each CSF sample the MCH/hypocretin-1 ratio. FLX tended to decrease the MCH/hypocretin-1 ratio (0.73 ± 0.48 in control group Vs. 0.36 ± 0.20 in FLX group, p = 0.057, t = 2.07).

The expression of Pmch gene in the hypothalamus did not change with FLX treatment (p = 0.55, t = −0.61) (Fig. 2A). In contrast, FLX treatment increased the level of the Hcrt mRNA (p = 0.02, t = −2.49; Fig. 2B).

4. Discussion

In the present study, we found that MCH concentrations in the CSF of normal rats decrease following subchronical treatment with FLX. This result is in agreement with the decrease in MCH serum level following 4 weeks of antidepressant treatment in depressive patients [30]. The diminution of MCH within the CSF could be mediated by a reduction in the activity of the MCHergic neurons. In fact, FLX increases serotonin synaptic levels [40], and serotonin hyperpolarizes MCHergic neurons [39]. In contrast, the expression of Pmch was not modified. These results suggest that FLX could be mediating a reduction in the release of the peptide rather than a decrease in its synthesis; however, measurements of the hypothalamic pre-proMCH protein are needed to confirm this hypothesis.

In agreement with these results, preclinical studies have involved MCH with depression; for example, local administration of MCH into the DRN induced a depressive-like behavior evaluated in the FST [19,38]. This effect was prevented by systemic and subchronic treatment with either FLX and nortriptline (a noradrenergic antidepressant) [19,38]. Furthermore, MCH immunoneutralization (i.e. anti-MCH antibodies microinjected into the DRN) elicited an antidepressant behavioral response in the FST [19]. Microinjections of MCH into the DRN not only produce a depressive-like effect that is prevented by antidepressant, but also produce a REM sleep hypersomnia [17,18,38], that is a classical trait of MD [1,3,26]. Georgescu et al. (2005) also showed an increase in the immobility time in the FST induced by bilateral microinjection of MCH into the nucleus accumbens [13], demonstrating that other brain areas are also involved in depressive-like behaviors induced by MCH.

Katai et al. (2013) have recently explored the effect of acute antidepressant treatment (escitalopram, also a SSRI) on c-fos expression in MCHergic neurons during REM sleep rebound [14]. They demonstrated that escitalopram decrease the number of active (Fos positive) MCHergic neurons, which is in agreement with the reduction of MCH concentration in the CSF observed in the present study, and in accordance with the hypothesis that the MCHergic system might be involved in the pathophysiology of depression.

Although there is growing evidence that involve the
hypocretinergic system in the pathophysiology of depression, its role is still controversial [24]. A recent study reported that there is a decrease in depressive-like behavior in hypocretin receptor-1 knockout mice, whereas hypocretin receptor-2 knockout mice exhibit an increase in the depressive-related behavior, pointing to a differential role for both hypocretinergic receptors in MD regulation [31]. Further, Nollet et al. [23] demonstrated that mice subjected to unpredictable chronic mild stress displayed increased depressive-like behavior following the tail suspension test and presented elevated hypocretinergic neuronal activity. These authors were able to reverse this elevation in the hypocretinergic activity with six weeks of FLX treatment. In human studies, Salomon et al. [29] reported that hypocretin-1 CSF levels were higher in MD patients, and treatment with sertraline, an SSRI antidepressant, resulted in an attenuation of CSF hypocretin-1 levels. Under our experimental conditions, FLX did not modify hypocretin-1 concentration in the CSF. Interestingly, FLX increased the propr- hypocretin mRNA level in the hypothalamus. These results suggest an eventual increase in the hypocretin synthesis without a perceptible effect on the release of the peptide toward the ventricular system. However, we cannot discard a local, slower and/or subtler effect upon hypocretin release that is not expressed in the CSF concentration. Since the hypocretinergic neurons are involved in reward and motivation [21], FLX might ameliorate the anhedonic component of depression by the modulation of the hypocretinergic system.

It has been suggested that the MCergic and hypocretinergic systems reciprocally regulates several physiological functions such as wakefulness and sleep [16]. It is likely that other functions, like mood, are also controlled in a reciprocally way by these systems. In this regards, FLX tended to decrease the MCH/hypocretin-1 concentration ratio (p=0.057). It is likely that FLX move the balance between the MCergic and hypocretinergic neuronal activity, down-regulating the first in favor of the hypocretinergic side of the equation. Finally, it is known that acute treatment with ketamine increases the antidepressant effect of FLX [25]. However, in our experiments, ketamine anesthesia as well as taps and freezing procedures lasted no more than 20 min, a time that should not be enough to alter neither the peptides CSF concentrations nor the gene expression. In addition, this procedure was done both in control and experimental animals; hence we consider that ketamine did not modify the results.

5. Conclusions and future directions

The subchronical treatment with FLX decreased the concentration of MCH in the CSF. In agreement with the fact that MCH antagonists have antidepressant effects, the effect of FLX upon the MCergic system is a new evidence that support the hypothesis that MCH is a pro-depressive factor. New experiments are needed in order to confirm and dissect the effect of classical antidepressant on the MCergic and hypocretinergic systems. A new series of experiments in animal models of depression (chronic mild stress, olfactory bulbectomy, etc.) are warranted [22]; we hypothesize that the effect of FLX should be even more pronounced in depressive individuals.

Acknowledgements

This study was supported by the “Proyecto de Cooperación Bilateral Uruguay - Brasil, Dicyt-CNPq”, ANII-FCE-1-2011-1-5997, Programa de Desarrollo de Ciencias Básicas (PEDECIBA), and Associação Fundo de Incentivo à Pesquisa (AFIP). VDA is recipient of a research fellowship obtained from CNPq. We are grateful to MSC, Matias Cavelli for his technical assistance. No conflict of interest to declare.

References

[1] Adrieen J. Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 2002;6:341–51.
[2] American-Psychiatric-Association. Diagnostic and statistical manual of mental disorders. DSM-5, Fifth Ed. Washington DC, 2013.
[3] Benca RM. Mood disorders, In: Ropper MH, Roth T, Dement WC, editors. Principles and practices of Sleep Medicine. Philadelphia: Elsevier-Saunders; 2005, p. 1311–26.
[4] Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, Vale W, Sawchenko PE. The melanin-concentrating hormone system of the rat brain: an immunocytochemical and histochemical characterization. J Comp Neurol 1992;319:218–45.
[5] Borovinsky B, Durkin MM, Oggozale K, Marzabadi MR, DeLee J, Heurich R, Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald C, Vayse PJ, Forray C. Antidepressant, anxiolytic and anorectic effects of a mel- anin- concentrating hormone-1 receptor antagonist. Nat Med 2002;8:825–30.
[6] Chaki S, Shimazaki T, Nishiguchi M, Funakoshi T, Iijima M, Ito A, Kamasu K, Shimokura Y. Antidepressant and anorectic potentiel and adverse effect liabilities of melanin-concentrating hormone receptor 1 antagonists in animal models. Pharmaco Biochem Behav 2015;135:154–68.
[7] Chase MH. A unified survival theory of the functioning of the hypocretinergic system. J Appl Physiol 2013;115:954–71.
[8] David DJ, Klemmenagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, Craig DA, Zhong H, Swanson CJ, Hegde LG, Ping XL, Dong D, Marzabadi MR, Gerald CP, Hen R. Efficacy of the MCHRI antagonist N-(3-([1-]{(4-phenyl)phenyl}){4-methylphenyl}{1-}(4-fluorophenyl)-1H-4-piperidyl)]-4-methylphenyl]-[2]-methylpropano-mide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogen- eris. J Pharmacol Exp Ther 2007;321:237–48.
[9] Devera A, Pascoievich C, Lagos P, Falconi A, Sampogna S, Chase MH, Torterolo P. Melanin-concentrating hormone (MCH) modulates the activity of dorsal raphé neurons. Brain Res 2015;1598:114–28.
[10] Dias Abdo Agamme AL, Aguilar Calegare BF, Fernandes L, Costa A, Lagos P, Torterolo P, D’Almeida V. MCH levels in the CSF, brain prepro-MCH and MCH1 gene expression during paradoxical sleep deprivation, sleep rebound and chronic sleep restriction. Peptides 2015;74:9–15.
[11] Garcia-Fuster MJ, Parks GS, Clinton SM, Watson SJ, Akil H, Civelli O. The melanin-concentrating hormone (MCH) system in an animal model of de- pression-like behavior. Eur Neuropsychopharmacol 2012;22:607–13.
[12] Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfo P, Craft I, Coskun T, Zhang HY, Chen Y, Wittink JM. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity and depression. J Pharmacol Exp Ther 2009;329:429–38.
[13] Georgescu D, Sears RM, Hommel JD, Barratt M, Bolanos CA, Marsh JD, Bednarak MA, Bibbo M, Maratos-Flier E, Nestler EJ, Dizzone BJ. The hypothalamic neu- rotropic melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J Neurosci 2005;25:2933–40.
[14] Katai Z, Adori C, Kikta T, Vas S, Kalmar L, Kostyalk D, Tothfalusi L, Palkovits M, Bagdy G. Acute escitalopram treatment inhibits REM sleep rebound and activa- tion of MCH-expressing neurons in the lateral hypothalamus after long term selective REM sleep deprivation. Psychopharmacology 2013;228:439–49.
[15] Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS. Prevalence and effects of mood dis- orders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006;163:1561–8.
[16] Kolodzie ER, Pelluru D, Noorani M, Pfay R, Pe, Neurons containing orexin or melanin-concentrating hormone reciprocally regulate wake and sleep. Front Syst Neurosci 2015;9:244.
[17] Lagos P, Torterolo P, Santos H, Chase MH, Monti JM. Effects on sleep of mel- anin-concentrating hormone microinjections into the dorsal raphe nucleus. Brain Res 2009;1265:103–10.
[18] Lagos P, Urbanavicius J, Scorza C, Miraballes R, Torterolo P. Depressive-like profile induced by MCH microinjections into the dorsal raphe nucleus evaluated in the forced swim test. Behav Brain Res 2011;218:259–66.
[19] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real- time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–8.
[20] McGregor R, Wu MF, Barber G, Ramanathan L, Siegel J, Highly specific role of hypocretin (orexin) neurons: differential activation as a function of dorsal phase, operant reinforcement versus operant avoidance and light level. J Neurosci 2011;31:15455–67.
[21] C, Menard, G.E., Hodes and S.J., Russo, Pathogenesis of depression: Insights
from human and rodent studies, Neuroscience (2015).

[23] Nollet M, Gaillard P, Minier F, Tanti A, Belzung C, Leman S. Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 2011;61:336–46.

[24] Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs 2013;27:411–22.

[25] Owolabi RA, Akanmu MA, Adeyemi OL. Effects of ketamine and N-methyl-D-aspartate on fluoxetine-induced antidepressant-related behavior using the forced swimming test. Neurosci Lett 2014;566:172–6.

[26] L., Palagini, C., Baglioni, A., Ciapparelli, A., Gemignani and D., Riemann, REM sleep dysregulation in depression: State of the art, Sleep Med Rev (2013).

[27] Peyron C, Tighe DK, van den Pol AN, de Leece L, Heller HC, Sutcliffe JG, Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998;18:9996–10015.

[28] Saito Y, Nagasaki H. The melanin-concentrating hormone system and its physiological functions. Results Probl Cell Differ 2003;54:96–104.

[29] Schmidt FM, Nowak C, Kratzsch J, Sander C, Hegerl U, Schonknecht P. Dynamics of melanin-concentrating hormone (MCH) serum levels in major depressive disorder during antidepressant treatment. J Affect Disord 2015;180:207–13.

[30] Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE, Nestler EJ, Elmquist JK, Lutter M. Hcrt1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res 2011;222:289–94.

[31] Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JC, VanMeter S, Harriott AE, Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974–81.

[32] Torterolo P, Chase MH. The hypocretins (orexins) mediate the "phasic" components of REM sleep: a new hypothesis. Sleep Science 2014;7:19–29.

[33] Torterolo P, Lagos J, Monti J. Melanin-concentrating hormone (MCH): a new sleep factor? Front Neurol 2011;2:1–12.

[34] Urbanavicius J, Lagos P, Torterolo P, Abin-Carriquiry JA, Scorza C. Melanin-concentrating hormone projections to the dorsal raphe nucleus: An immunofluorescence and in vivo microdialysis study. J Chem Neuroanat 2016;72:16–24.

[35] Urbanavicius J, Lagos P, Torterolo P, Scorza C. Pro-depressive effect induced by microinjections of MCH into the dorsal raphe: time-course, dose-dependence, effects on anxiety-related behaviors and reversion by nortriptyline. Behav Pharmacol 2014;25:316–24.

[36] van den Pol AN, Acuna-Goycolea C, Clark KR, Ghosh PK. Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection. Neuron 2004;42:635–52.

[37] Wenthur CJ, Bennett MR, Lindsey CW. Classics in chemical neuroscience: fluoxetine (prozac). ACS Chem Neurosci 2014;5:14–23.